Cytokinetics INC Form 4 insider transactions

Director Wendell Wierenga acquired 95 shares of Cytokinetics common stock as part of a director equity compensation program.

Director Edward M. Kaye acquired 191 shares of Cytokinetics common stock as part of a director equity compensation program.

Director John T. Henderson acquired 325 shares of Cytokinetics common stock through the company's equity-in-lieu-of-cash program.

Director Robert Arthur Harrington acquired 191 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Director James M. Daly acquired 191 shares of Cytokinetics common stock as part of the company's Director Equity in Lieu of Cash Retainer Program.

EVP and Chief Commercial Officer Andrew Callos sold 7,449 shares of Cytokinetics common stock on April 15, 2026.

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock on April 15, 2026.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, reported transactions involving the acquisition and sale of common stock and stock options.

Cytokinetics President and CEO Robert I. Blum filed a Form 4 indicating a planned sale of 7,500 common shares on April 1, 2026, under a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported the sale of 3,639 common shares at $65 per share, executed under a pre-arranged 10b5-1 trading plan.

Cytokinetics' EVP and CFO, Sung Lee, sold 4,935 shares of common stock at $62.15 per share to cover tax withholding obligations related to RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 8,542 shares of common stock to cover tax withholding obligations from RSU vesting.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, sold 12,033 shares of common stock to satisfy tax withholding obligations from RSU vesting.

Cytokinetics' President & CEO, Robert I. Blum, sold shares to cover tax withholding obligations from RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 1,930 shares of common stock for $62.07 per share in a pre-planned transaction.

Cytokinetics' President and CEO, Robert I. Blum, received annual equity awards including restricted stock units and stock options.

Cytokinetics' EVP and Chief Commercial Officer, Andrew Callos, was granted significant equity awards, including restricted stock units and stock options, effective March 15, 2026.

Cytokinetics' Chief Legal & Admin Officer, Jeffrey Hessekiel, was granted significant equity awards including restricted stock units and stock options on March 15, 2026.

CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, received significant equity awards including restricted stock units and stock options.

Cytokinetics EVP Andrew Callos sold 1,709 shares of common stock for $61.03 per share under a pre-arranged trading plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold a portion of his common stock holdings on March 5, 2026.

Cytokinetics Director B. Lynne Parshall sold 5,000 shares of common stock at $61.21 per share in a pre-planned transaction.

Cytokinetics' Chief Commercial Officer, Andrew Callos, exercised stock options and simultaneously sold an equal number of shares under a pre-arranged 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares in a pre-planned transaction.

Cytokinetics Director James M. Daly acquired 197 shares of common stock at $63.44 per share, opting for equity in lieu of a cash retainer.

Cytokinetics Director Nancy Wysenski acquired 98 shares of common stock at $63.44 per share, increasing her direct beneficial ownership to 30,971 shares.

Cytokinetics Director Wendell Wierenga acquired 98 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director Edward M. Kaye MD acquired 197 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director John T. Henderson acquired 334 shares of common stock at $63.44 per share as equity compensation.